-
March 23, 2024
GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes
-
March 07, 2024
A chemically inducible IL-2 receptor signaling complex allows for effective in vitro and in vivo selection of engineered CD4+ T cells
-
June 20, 2023
Human Engineered Tregs maintain stability in inflammatory environment (Poster)
-
May 23, 2023
Development of GNTI-122, a novel engineered regulatory T cell therapeutic, for future application in type 1 diabetes (Poster)
-
May 16, 2023
GNTI-122 is a Dual-Engineered Regulatory T Cell Therapy Product for Type 1 Diabetes with Enhanced Stability, Tissue Specificity, and Tunable IL-2 Signaling (Poster)
-
June 05, 2022
Characterization and efficacy of engineered regulatory T-cell therapy, GNTI-122, for treating Type 1 Diabetes (Poster)
-
May 18, 2022
Generation of Islet-specific Engineered Regulatory T Cells (EngTregs) for Immune Tolerance Induction in Type 1 Diabetes Using a Novel Dual-editing Strategy
-
June 03, 2020
Gene editing to induce FOXP3 expression in human CD4+ T cells leads to a stable regulatory phenotype and function